Anixa Biosciences (ANIX) Stock
Clinical stage biotech developing immune treatments and diagnostics. Here's the price, business snapshot, and what's worth knowing about Anixa Biosciences in September 2026.
Anixa Biosciences, Inc. (ANIX) is a small-cap, clinical-stage biotechnology company focused on developing immunotherapies and diagnostic technologies. Investors should know it operates in a high-risk, high-reward segment: progress depends heavily on clinical trial outcomes, regulatory decisions and successful commercialisation of any products. With a market capitalisation of about $137.6m, liquidity and analyst coverage may be limited, which can increase share-price volatility. Key potential value drivers include trial readouts, regulatory milestones, strategic partnerships and diagnostic adoption; conversely, setbacks, funding needs and dilution are common risks for companies at this stage. For those tracking ANIX, review company filings, press releases, clinicaltrials.gov entries and quarterly cash-flow reports to gauge runway and progress. This summary is for general education only, not personalised investment advice. Consider your risk tolerance and diversification needs, and consult a financial professional before making investment decisions.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Anixa Biosciences' stock with a target price of $7, indicating significant growth potential.
Financial Health
Anixa Biosciences is managing its cash flow and has a decent book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Trial readouts and regulatory milestones can materially affect valuation — though outcomes are uncertain and setbacks are common.
Technology Focus
Focus on immunotherapies and diagnostics may offer long-term opportunities if programmes succeed, but development and commercial risks remain significant.
Market Dynamics
As a small-cap biotech with ~ $137.6m market cap, ANIX can be volatile and may face liquidity or funding challenges; diversification helps manage risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
